Cover Image
市場調查報告書

印度的學名藥市場預測:2020年

Indian Generic Drug Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 339856
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
印度的學名藥市場預測:2020年 Indian Generic Drug Market Outlook 2020
出版日期: 2015年09月01日 內容資訊: 英文 90 Pages
簡介

印度的學名藥市場,預計2014年∼2020年以16.3%的年複合成長率成長。

本報告提供印度的學名藥市場相關調查分析、目前市場方案、主要趨勢與推動因素、市場機會、競爭情形、未來預測等系統性資訊。

第1章 分析師的見解

第2章 調查手法

第3章 印度的製藥市場預測

第4章 推動因素

  • 醫療費的上升
  • 可支配所得的增加
  • 高齡人口的增加
  • 文明病的劇增
  • 進行中的專利懸崖 (Patent Cliff)

第5章 課題

  • 跟品牌藥的競爭
  • 缺乏價格統一控制
  • 弱的供應鏈管理
  • 推銷不足
  • 品管
  • 認識不足

第6章 供應鏈模式

第7章 法規形勢

第8章 印度的非專利概要

  • 印度市場實際成果
  • 市場規模
  • 全球主要學名藥
  • 主要的非專利市場區隔

第9章 非專利產業的整合

第10章 政府的配合措施

第11章 競爭

  • 主要企業的市場佔有率
  • 簡介
    • Sun Pharma
    • Cipla Limited
    • Biocon
    • Dr. Reddy's Laboratories
    • Lupin Ltd.
    • Aurobindo Pharma Limited
    • Wockhardt
    • Zydus Cadila
    • Glenmark
    • Jubilant LifeSciences

第12章 未來預測

第13章 非專利產業:前途

  • 機會
  • 建議

圖表

目錄

Generics drugs are bioequivalent versions of the originator medicines. These drugs are cheaper and offer similar health benefits as those of branded counterparts. Generics are showing high penetration in the pharma market across the globe. In India, these drugs account for nearly 75% of the pharma market. This is due to the factors, such as rising healthcare expenditure, ageing population, high incidences of obesity, diabetes and cardiovascular diseases, as well as ongoing patent cliff of blockbuster drugs in the US and European markets. India is a market dominated by branded generics. Approximately 80% of the generics are off-patented drugs sold under brand names by big pharmaceutical companies like Pfizer, Bristol-Myer-Squibb and Glaxosmithkline among others. Branded generics are available at very high cost leading to affordability issues, particularly in rural india.

In the report “Indian Generic Drug Market Outlook 2020”, RNCOS analysts have endeavoured to address the current scenario of generics drug industry, factors favouring growth of the market, major roadblocks for the lack of penetration of unbranded drugs, and government initiatives to promote generic drugs. The report covers detailed description of the market size of generic drugs and its future forecast till 2020. Additionally, market segmentation of generic drugs by therapeutic segments is also included. RNCOS predicts that owing to the implementation of government schemes, like Jan Aushadhi, Free essential drug, and Sehat, the unbranded generic drug market is likely to show a promising growth in the near future. The generic drug market is anticipated to grow at a CAGR of 16.3% from 2014-2020.

The latter half of the report provides competitive landscape including the market shares of key players, such as Sun-Pharma, Dr. Reddys, Cipla, Lupin, Biocon, and others. Finally, a separate section comprising of opportunity assessment for the domestic generic manufactures is also added. The last part of the report describes several steps that need to be taken by the Government to promote unbranded drugs. On the whole, the report provides information that will prove to be vital for investors interested in the domestic market.

Table of Contents

1. Analyst View

2. Research Methodology

3. India Pharmaceutical Market Outlook

4. Drivers

  • 4.1. Rising Healthcare Expenditures
  • 4.2. Increasing Disposable Incomes
  • 4.3. Growing Ageing Population
  • 4.4. Surging Lifestyle Diseases
    • 4.4.1. Cardiovascular Diseases
    • 4.4.2. Diabetes
    • 4.4.3. Cancer
  • 4.5. Ongoing Patent Cliff

5. Challenges

  • 5.1. Competition from Branded Drugs
  • 5.2. Lack of Price-Control
  • 5.3. Weak Supply Chain Management
  • 5.4. Lack of Promotion
  • 5.5. Quality Control
  • 5.6. Lack of Awareness

6. Supply Chain Model

7. Regulatory Landscape

8. India Generic Overview

  • 8.1. Indian Market Performance Relative to the World
  • 8.2. Market Size
  • 8.3. Top Generic Drugs Globally
  • 8.4. Major Generic Segments

9. Consolidations in Generics Industry

10. Government Initiatives

  • 10.1. Jan Aushadhi Scheme for the promotion of Generics Drugs
  • 10.2. Free Essential Drug Scheme
  • 10.3. Telemidicine Initiative “Sehat”

11. Competition

  • 11.1. Market Share of Major Players
  • 11.2. Profiles
    • 11.2.1. Sun Pharma
    • 11.2.2. Cipla Limited
    • 11.2.3. Biocon
    • 11.2.4. Dr. Reddy's Laboratories
    • 11.2.5. Lupin Ltd.
    • 11.2.6. Aurobindo Pharma Limited
    • 11.2.7. Wockhardt
    • 11.2.8. Zydus Cadila
    • 11.2.9. Glenmark
    • 11.2.10. Jubilant LifeSciences

12. Future Outlook

13. Generic Industry: The Road Ahead

  • 13.1. Opportunities
  • 13.2. Recommendations

List of Figures:

  • Figure 3-1: Breakdown of India Pharmaceutical Market by Value (%) 2009-2014
  • Figure 3-2: Domestic Pharmaceutical Market (Billion US$) 2014-2020
  • Figure 4-1: Healthcare Expenditure (% of GDP) 2009-2014
  • Figure 4-2: Personal Disposable Income (Billion US$) 2009-2014
  • Figure 4-3: Population Above 65 Years (Million) 2009-2014
  • Figure 4-4: Diabetes Population (20-79 Years) Million 2013 & 2030
  • Figure 4-5: Number of Cancer Cases (‘000) 2014 & 2020
  • Figure 6-1: Generic Supply Chain
  • Figure 7-1: Hierarchy of Ministry for Generic Drug Regulation
  • Figure 8-1: Share of India in Global Generics Market (%) 2014
  • Figure 8-2: India Generics Drug Market (Billion US$) 2009-2014
  • Figure 8-3: Revenue Share of Major Generics Segments (%) 2014
  • Figure 11-1: Sun Pharma - Break up of Revenue by Therapeutic Segment (%), 2014
  • Figure 11-2: Sun Pharma - Break up of Revenue by Geography (%), 2014
  • Figure 11-3: Cipla Limited - Break up of Revenue by Geography (%), 2014
  • Figure 11-4: Biocon - Break up of Revenue by Geography (%), 2014
  • Figure 11-5: Dr. Reddy's Laboratories - Break up of Revenue by Geography (%), 2014
  • Figure 11-6: Lupin Limited - Revenues by Trade (Billion US$), 2014
  • Figure 11-7: Aurobindo Pharma Limited - Break up of Formulations Revenue of by Geography (%), 2014
  • Figure 11-8: Wockhardt - Break up of Revenue by Geography (%), 2014
  • Figure 11-9: Zydus Cadila - Break up of Revenue by Geography (%), 2014
  • Figure 11-10: Glenmark - Break up of Revenue by Geography (%), 2014
  • Figure 11-11: Jubilant LifeSciences - Break up of Revenue by Geography (%), 2014
  • Figure 12-1: Generics Drug Market (Billion US$) 2014-2020

List of Tables:

  • Table 4-1: List of Blockbustor Drugs Losing Patent (2015-2020)
  • Table 8-1: Similarities and Differences Between Branded & Generics Drugs
  • Table 8-2: Top Generic Drugs Globally by Prescription (Million) 2014
  • Table 9-1: Major Consolidations in Indian Generic Industry (2014-2015)
  • Table 10-1: Comparative analysis of Jan Aushadhi Scheme (2008 & 2013)
  • Table 10-2: Pricing Details of Medicines under JAS Scheme
  • Table 10-3: Free Drugs Provided by States
  • Table 11-1: Market Share of Key Generics Players (%), 2014
  • Table 11-2: Sun Pharma - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 11-3: Biocon - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 11-4: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 11-5: Lupin Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 11-6: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 11-7: Zydus Cadila - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 11-8: Glenmark - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 11-9: Jubilant LifeSciences - Revenues by Business Segment (Billion US$), 2013 & 2014
Back to Top